Table 1. Clinical and biologic features... | American Society of Hematology

Table 1.

Clinical and biologic features of informative patients

Patient no.	Diagnosis	Age at diagnosis (y)	Duration of disease (y)	Hgb g/L	Platelets 10³/μL	Splenomegaly	Therapy at time of analysis	Therapy prior to analysis	TA (PMN)	Clonality (PMN)
1	ET	95	1	131	736	N	HU	—	103	C
2	PV	60	9	127	200	N	HU	HU	1	P
3	ET	68	14	126	794	N	—	HU	47.6	C
4	PV	69	1	158	749	Y	—	N	127.7	C
5	PV	72	3	193	311	N	HU	HU	89.6	C
6	ET	68	17	135	721	Y	HU	HU	212.5	C
7	PV	63	1	164	583	N	—	—	197	C
8	PV	78	3	184	603	Y	HU	P, HU	24.7	P
9	ET	62	3	165	750	N	HU	HU	2.1	P
10	ET	76	3	138	883	Y	HU	A, HU	123.7	C (LOH)
11	ET	61	9	158	769	N	HU	HU	19	P
12	ET	76	9	168	900	N	HU	HU	105	C
13	ET	78	12	146	740	N	—	B	10.8	P
14	PV	77	16	194	600	N	HU	P, HU	95	C
15	ET	79	6	143	795	N	—	B	70	C
16	PV	57	14	190	341	Y	P, HU	P, HU, A	83.7	C
17	ET	53	15	127	900	N	HU, A	HU	146.5	C
18	ET	63	14	135	480	N	HU	HU	10	P
19	ET	88	15	125	800	Y	HU	HU	119	C
20	ET	62	1	128	950	N	HU	—	90	C
21	PV	77	0	180	280	Y	—	—	162	C
22	PV	28	1	176	821	N	—	—	33.3	P

Patient no.	Diagnosis	Age at diagnosis (y)	Duration of disease (y)	Hgb g/L	Platelets 10³/μL	Splenomegaly	Therapy at time of analysis	Therapy prior to analysis	TA (PMN)	Clonality (PMN)
1	ET	95	1	131	736	N	HU	—	103	C
2	PV	60	9	127	200	N	HU	HU	1	P
3	ET	68	14	126	794	N	—	HU	47.6	C
4	PV	69	1	158	749	Y	—	N	127.7	C
5	PV	72	3	193	311	N	HU	HU	89.6	C
6	ET	68	17	135	721	Y	HU	HU	212.5	C
7	PV	63	1	164	583	N	—	—	197	C
8	PV	78	3	184	603	Y	HU	P, HU	24.7	P
9	ET	62	3	165	750	N	HU	HU	2.1	P
10	ET	76	3	138	883	Y	HU	A, HU	123.7	C (LOH)
11	ET	61	9	158	769	N	HU	HU	19	P
12	ET	76	9	168	900	N	HU	HU	105	C
13	ET	78	12	146	740	N	—	B	10.8	P
14	PV	77	16	194	600	N	HU	P, HU	95	C
15	ET	79	6	143	795	N	—	B	70	C
16	PV	57	14	190	341	Y	P, HU	P, HU, A	83.7	C
17	ET	53	15	127	900	N	HU, A	HU	146.5	C
18	ET	63	14	135	480	N	HU	HU	10	P
19	ET	88	15	125	800	Y	HU	HU	119	C
20	ET	62	1	128	950	N	HU	—	90	C
21	PV	77	0	180	280	Y	—	—	162	C
22	PV	28	1	176	821	N	—	—	33.3	P

ET indicates essential thrombocythemia; PV, polycythemia vera; C, monoclonal; P, polyclonal; LOH, loss of heterozygosity; A, anagrelide; B, busulfan; HU, hydroxurea; P, phlebotomy; and TA, telomerase activity in TPG units.

— indicates no therapy.

View Large

This Feature Is Available To Subscribers Only